COMP <GO>
AEON vs NEUP // REVENUE GROWTH (YOY)
AEON Biopharma Inc. (Class A) (NYSE) VS. Neuphoria Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: AEON 2
— NEUP 2
■ METRIC PARITY
LAST: $0.29 (+11.36%) • MKT CAP: $17.4M
revenue-growth
—
LAST: $3.06 (-8.93%) • MKT CAP: $16.6M
revenue-growth
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AEON VS. NEUP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AEON | NEUP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -11.80% | -23.20 | NEUP | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 0.47% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -7.20% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -2.40% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 5/9 | -4.00 | NEUP | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.6 | 26.4 | +32.20 | AEON | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $17.4M | $16.6M | $812.2K | AEON | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AEON REV | NEUP REV | AEON GROSS % | NEUP GROSS % | AEON FCF | NEUP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $15.6M | — | — | -$17.3M | $77.2K |
| FY 2024 | $0 | $0 | — | — | -$20.3M | -$14.7M |
| FY 2023 | — | $0 | — | — | — | -$14.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AEON // BETA —
NEUP // BETA —